HRP20000559A2 - Petrolatum-based nose ointment - Google Patents
Petrolatum-based nose ointment Download PDFInfo
- Publication number
- HRP20000559A2 HRP20000559A2 HR20000559A HRP20000559A HRP20000559A2 HR P20000559 A2 HRP20000559 A2 HR P20000559A2 HR 20000559 A HR20000559 A HR 20000559A HR P20000559 A HRP20000559 A HR P20000559A HR P20000559 A2 HRP20000559 A2 HR P20000559A2
- Authority
- HR
- Croatia
- Prior art keywords
- saturated hydrocarbons
- mixture
- ointment
- nasal
- inhalant
- Prior art date
Links
- 239000002674 ointment Substances 0.000 title claims abstract description 6
- 239000004264 Petrolatum Substances 0.000 title claims description 11
- 229940066842 petrolatum Drugs 0.000 title claims description 11
- 235000019271 petrolatum Nutrition 0.000 title claims description 11
- 229940100657 nasal ointment Drugs 0.000 claims abstract description 22
- 229930195734 saturated hydrocarbon Natural products 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 239000000654 additive Substances 0.000 claims abstract description 6
- 206010020751 Hypersensitivity Diseases 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 8
- 238000011321 prophylaxis Methods 0.000 claims description 7
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 6
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 5
- -1 pantenyl triacetate Chemical compound 0.000 claims description 5
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 4
- 235000004866 D-panthenol Nutrition 0.000 claims description 4
- 239000011703 D-panthenol Substances 0.000 claims description 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 4
- 201000010105 allergic rhinitis Diseases 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 208000030961 allergic reaction Diseases 0.000 claims description 3
- 230000035515 penetration Effects 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 claims description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 2
- 235000019489 Almond oil Nutrition 0.000 claims description 2
- 235000003880 Calendula Nutrition 0.000 claims description 2
- 240000001432 Calendula officinalis Species 0.000 claims description 2
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 2
- 240000000950 Hippophae rhamnoides Species 0.000 claims description 2
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims description 2
- 239000004166 Lanolin Substances 0.000 claims description 2
- 244000042664 Matricaria chamomilla Species 0.000 claims description 2
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 229960000458 allantoin Drugs 0.000 claims description 2
- 239000008168 almond oil Substances 0.000 claims description 2
- 235000021302 avocado oil Nutrition 0.000 claims description 2
- 239000008163 avocado oil Substances 0.000 claims description 2
- 229960003949 dexpanthenol Drugs 0.000 claims description 2
- 235000019388 lanolin Nutrition 0.000 claims description 2
- 229940039717 lanolin Drugs 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 229940101267 panthenol Drugs 0.000 claims description 2
- 235000019161 pantothenic acid Nutrition 0.000 claims description 2
- 239000011713 pantothenic acid Substances 0.000 claims description 2
- 229940055726 pantothenic acid Drugs 0.000 claims description 2
- 235000020957 pantothenol Nutrition 0.000 claims description 2
- 239000011619 pantothenol Substances 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims description 2
- 239000010497 wheat germ oil Substances 0.000 claims description 2
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 claims 1
- GMBVYJOWNGZGMU-NSHDSACASA-N [(3r)-4-(3-ethoxypropylamino)-3-hydroxy-2,2-dimethyl-4-oxobutyl] acetate Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)COC(C)=O GMBVYJOWNGZGMU-NSHDSACASA-N 0.000 claims 1
- 238000009835 boiling Methods 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 229940023735 panthenyl ethyl ether Drugs 0.000 claims 1
- 229940114156 panthenyl ethyl ether acetate Drugs 0.000 claims 1
- 239000012188 paraffin wax Substances 0.000 claims 1
- 230000035876 healing Effects 0.000 abstract 1
- 239000013566 allergen Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 5
- 210000001331 nose Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 210000003800 pharynx Anatomy 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Natural products CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229960003504 silicones Drugs 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Ovaj izum odnosi se na mast za nos koji se sastoji od smjesa, koje su na sobnoj temperaturi poput gela, prevladavajuće od zasićenog ugljikovodika, a za upotrebu u cilju profilakse inhalatornih alergijskih reakcija, posebno atopičnog rinitisa u obliku "peludne groznice". U pretpostavljenoj izvedbi, mast za nos prema ovom izumu sadrži također bar jedan aditiv za njegu prikladan za mast.
U zapadnjačkoj industrijaliziranoj civilizaciji inhalatorne alergije su sada vrlo raširene i imaju stalni trend povećanja. Radi se, posebno, o oblicima atopičnog rinitisa do kojih dolazi udisanjem polena, spora gljiva, različitih prašina (na primjer drvene, podne ili kućne prašine), te kemijskih ili životinjskih iritanata (perje, dlaka), što svojim popratnim manifestacijama može tako oštetiti zdravlje bolesnika da ga onesposobi za rad.
Neugodan svrbež nosa, farinksa, stražnje strane grla i očiju, nakon čega slijede suze u očima, kihanje i vodeni iscjedak iz nosa, često su popraćeni glavoboljom, razdražljivošću, gubitkom teka, depresijom i nesanicom. Nakon toga može doći do napadaja kašlja i astmatičnog hripanja.
Kao sezonska reakcija uzrokovana polenom s drveća, grmlja, trava i divljih ili ukrasnih biljaka, takozvana "peludna groznica" je najčešći oblik atopičnog hnitisa.
Većina suvremenih terapijskih i profilaktičkih mjera za kontrolu ili eliminaciju inhalatornih alergija pokazuje više ili manje ozbiljne nedostatke u vezi s troškovima, djelotvornošću, nuspojavama na zdravlje i prikladnošću upotrebe.
Tako, liječenje koje zahtijeva da se bolesnik tijekom nekoliko tjedana peludne sezone ukloni iz područja izloženosti u područja s manje peludi, kao što su velika nadmorska visina ili otoci s malo vegetacije, ili da promijeni mjesto stanovanja ili rada kako bi izbjegao izloženost peludu, mnogi si bolesnici vrlo teško mogu priuštiti.
Ovo izbjegavanje izlaganju peludu uključuje i pokušaj da se što je više moguće iz bolesnikove okoline uklone alergeni koji uzrokuju poremećaj.
Potpuno uklanjanje udisanja alergena je nemoguće. Postoji samo mogućnost uklanjanja kontaktnih površina s alergenima, to jest sluznice kao mjesta reakcije. To je opisano kao djelomično izbjegavanje izlaganja.
Postavljanjem alergenskih filtera u ventilaciju i sustave za klimatizaciju u stanovima, radnim prostorijama i automobilima moguće je spriječiti izlaganje peludu samo u takvim posebno zaštićenim područjima, ali je to povezano s nezanemarivim troškovima.
Nošenje respiratora preko nosa i usta opravdano je s obzirom na cijenu i djelotvornost, ali je neprikladno.
Desenzibilizacija (hiposenzibilizacija, imunizacija) zahtijeva opsežne pretrage radi izbora djelotvornog antigenskog ekstrakta. I unatoč tome, ne može se sa sigurnošću predvidjeti hoće li ishod liječenja biti kliničko poboljšanje. Osim toga, ova metoda sadrži opasnost od popratnih pojava pogibeljnih po zdravlje, kao što su, na primjer, astmatoidni i urtikarijski simptomi. Dalje, liječenje desenzibilizacijom zahtijeva relativno veliki utrošak vremena i novca.
Simptomatsko liječenje alergijskih reakcija pomoću oralnih antihistamina u cilju smanjivanja otoka sluznice povezano je kod mnogih takvih proizvoda s opasnošću sedativnog djelovanja, koji ima suprotan učinak na zdravlje i brzinu reakcija. Osim toga, nisu neuobičajene i nuspojave poput, na primjer, glavobolje, suhoće usta i poremećaja koncentracije.
Nadalje, upotreba, koja se također primjenjuje, simpatomimetika, proizvoda na osnovi kromoglicilne kiseline i glukokortikoida, također ima nedostataka zbog mnogih nuspojava i/ili visokih troškova.
Radi detaljnog opisa ove ranije navedene namjere pozivamo se na DE-C 41 17 887. To se odnosi na primjenu zasićenih ugljikovodika, koji se farmaceutski/kozmetićki definiraju kao petrolat, kao mast za nos radi profilakse inhalatornih alergijskih reakcija, posebno tipa "peludne groznice", s time da petrolat koji se u njemu upotrebljava ima sljedeće osobine:
- stinište po metodi DIN 51 556: 49 do 52°C;
- viskozitet po metodi DIN 51 562; 6 mm2/s (100°C);
- konično prodiranje po metodi DIN 51 580:150 do 170;
- prosječna duljina lanca ugljikovodika u petrolatu: 26 ± 1 C atom;
- raspon brojeva C u ugljikovodicima: C15 do C60.
S obzirom na ranije navedenu namjeru, cilj na kojem se osniva ovaj izum bio je poboljšano mazanje nosa radi pouzdanog profilaktičkog učinka na inhalatorne alergijske reakcije na osnovi dalje poboljšanog petrolata. Namjena ove masti za nos bila je da ne povlači za sobom opasnost po zdravlje bolesnika, da ima širok raspon djelovanja protiv različitih alergena u udahnutom zraku, da bude ugodna za upotrebu i, konačno, da troškovi liječenja budu niski.
Ova i druge namjene postižu se pomoću masti za nos prema Zahtjevu 1, to jest pomoću masti za nos za profilaksu inhalatornih alergijskih reakcija koja se sastoji od najmanje jedne smjese zasićenih ugljikovodika.
Kao suprotnost petrolata opisanog u DE-C 41 17 887, petrolat koji se sada upotrebljava prema ovom izumu ima veću proporciju zasićenih ugljikovodika dugog lanca.
Nema ograničenja za petrolat koji može biti korišten prema ovom izumu, jer je on u skladu sa zahtjevima čistoće kvalitete koja se može primjenjivati u farmaciji i kozmetici prema DAB odredbama čistoće i ima potrebne parametre prema izumu u odnosu na uobičajena svojstva.
Tako, petrolat upotrebljen prema ovom izumu ima viskozitet na 100°C po metodi DIN 51 562 > 6 mm2/s poželjno > 8 mm2/s, a napose viskozitet od 8,5 do 15 mm2/s.
U daljnjoj poželjnoj izvedbi upotrebljava se petrolat koji ima najmanje jedno od sljedećih svojstava a) do e):
a) stinište (DIN 51 556) 47 do 56°C;
b) konično prodiranje prema metodi DIN 51 580 od 155 do 185;
c) maksimum od 5% težine zasićenih ugljikovodika ima duljinu lanca od ≤ 25 ± 2;
d) raspon brojeva C zasićenih ugljikovodika (GC determinacija): sadrži C19 do C32, u svakom slučaju i.2; te
e) brojčanu prosječnu molekularnu težinu: > 400, poželjno > 480, a napose > 500 g/mol.
Dodaci za njegu za masti koji se mogu upotrebljavati su svi poznati aditivi u tu svrhu, a najbolje silikoni, pantenol, lanolin, lecitin, dekspantenol, provitamin B5, pantotenska kiselina, pantenil etil eter, pentenil etil eter acetat, pantenil triacetat, alantoin, biljna (alge, lišaj) ulja, kao što su, na primjer, bademovo ulje, ulje od pšeničnih klica, ulje avokada, voskovi kao što su, na primjer, parafini, ekstrakti, poželjno ekstrakti CO2, kao što su, na primjer, kamilica, morski trn i calendula.
Mast za nos prema ovom izumu može se nanositi prstom ili aplikatorom. Međutim, radi zaštitnog djelovanja protiv inhalatornih alergijskih reakcija bitno je mjesto njegove primjene u nosu. U cilju postizanja pouzdane profilakse treba osigurati da unutarnje površine nosa budu pokrivene mašću u predjelu dvaju nosnih odušaka.
Ako se mast za nos prema ovom izumu primjenjuje samo na donji kraj nosnog vestibula u predjelu vanjskih nosnica, nemoguće je spriječiti inhalatornu alergijsku reakciju. Međutim, pri pravilnoj primjeni, moguće je pomoću masti za nos prema ovom izumu postići djelomično izbjegavanje izlaganju udahnutim alergenima. Budući da mast za nos prema ovom izumu ne može, zbog svojih posebnih fizičkih svojstava, prodrijeti u sluznicu nosa i apsorbirati se, nego ostaje na mjestu kao zaštitni film, stvarajući mehaničku zapreku protiv nositelja alergena koje pokupi i prenosi respiratorna struja. Na taj način je moguće značajno spriječiti alergijsku reakciju.
Kao što je već opisano u DE-C 41 17 887, osnovna prednost ovog izuma je da ne dolazi do alergijskih reakcija, pa nema potrebe da se bolesnikov metabolizam izlaže sistemskim aktivnim sastojcima. Glavni sastojci masti za nos, spomenuti zasićeni ugljikovodici, po ponašanju su inertni i ne apsorbiraju se. To znači da se mast za nos prema ovom izumu može upotrebljavati bez ikakve opasnosti. Osim toga, ne dolazi ni do smanjenja učinkovitosti uzrokovanog privikavanjem bolesnikovog tijela na mast. Sposobnost razlikovanja mirisa i, stim u vezi, okusa ostaje nepromijenjena.
Daljnje prednosti masti za nos prema ovom izumu, koje se mogu spomenuti, jesu:
- komparativno niski troškovi;
- bolesnik može sam obavljati preventivnu primjenu;
- primjena masti za nos prema ovom izumu, osim toga, istovremeno djeluje kao njega.
Nadalje, mast za nos prema ovom izumu ne samo da je u stanju spriječiti otečenost, pražnjenje i svrbež u unutrašnjosti nosa pri izlaganju alergenu, nego može ukloniti i nadražujuće reakcije u predjelima očiju i grla.
Prema tome, ovaj se izum također odnosi na upotrebu najmanje jedne smjese, farmaceutski/kozmetički definirane kao petrolat, od zasićenih ugljikovodika kako je navedeno u bilo kojem od Zahtjeva 1 do 5 ili kao mast(i) za nos za profilaksu inhalatornih alergijskih reakcija, s time da je posebno u stanju imati blagotvorno djelovanje na atopični rinitis tipa "peludne groznice".
Kao zaključak, može se također spomenuti da se, zbog velike djelotvornosti masti za nos prema ovom izumu i njezine upotrebe prema ovom izumu, postiže dugotrajni, pouzdani zaštitni učinak, premda ju je dovoljno primijeniti u vrlo malim količinama. S količinom od nekoliko miligrama, koja se namaže ispred nosnih odušaka, moguće je na nekoliko sati postići oslobađanje od simptoma, čak i pri velikoj količini peluda, bez potrebe za ponovnom primjenom masti za nos prema ovom izumu.
Claims (7)
1. Mast za nos za profilaksu inhalatornih alergijskig reakcija koja sadrži najmanje jednu smjesu zasićenih ugljikovodika naznačena time da barem jedna smjesa zasićenih ugljikovodika ima viskozitet prema metodi DIN 51 562 od > 6 mm2/s (100°C).
2. Mast za nos prema Zahtjevu 1, naznačena time da barem jedna smjesa zasićenih ugljikovodika ima manje od 25% po težini linearnih zasićenih ugljikovodika (n-parafini).
3. Mast za nos prema Zahtjevima 1 ili 2, naznačena time da bar jedna smjesa zasićenih ugljikovodika ima bar jedno od sljedećih svojstava:
a) stinište (ISO 2207) 47 do 56°C;
b) konično prodiranje prema metodi DIN 51 580 od 155 do 185;
c) maksimum 5% po težini zasićenih ugljikovodika ima duljinu lanca od ≤ 25 ± 2;
d) raspon brojeva C zasićenih ugljikovodika (GC determinacija): sadrži C19 do C52, u svakom slučaju ± 2; te
e) brojčanu prosječnu molekularnu težinu: > 400, poželjno > 480, a napose > 500 g/mol.
4. Mast za nos prema bilo kojem Zahtjevu 1 do 3, naznačena time da dodatno sadrži bar jedan od aditiva za njegu.
5. Mast za nos prema Zahtjevu 4, naznačena time da se aditiv za njegu odabire između silikona, pantenola, lanolina, lecitina, dekspantenola, provitamina B5, pantotenske kiseline, pantenil etil etera, pantenil etil eter acetata, pantenil triacetata, alantoina, bademovog ulja, ulja pšeničnih klica, ulja avokada, parafina i CO2 ekstrakata kamilice, morskog trna i calendule, kao i smjese dvaju ili više navedenih sastojaka.
6. Upotreba najmanje jedne smjese naznačena time da se farmaceutski/kozmetički definira kao petrolat, od zasićenih ugljikovodika kako je navedeno u bilo kojem od Zahtjeva 1 do 5 ili kao mast(i) za nos za profilaksu inhalatornih alergijskih reakcija.
7. Upotreba prema Zahtjevu 6, naznačena time da je inhalatorna alergijska reakcija atopični rinitis tipa "peludne groznice".
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE20009841U DE20009841U1 (de) | 2000-05-31 | 2000-05-31 | Nasensalbe auf Basis von Vaselin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20000559A2 true HRP20000559A2 (en) | 2001-12-31 |
Family
ID=7942316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20000559A HRP20000559A2 (en) | 2000-05-31 | 2000-08-28 | Petrolatum-based nose ointment |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20030161899A1 (hr) |
| EP (2) | EP1159958A1 (hr) |
| JP (2) | JP2001342131A (hr) |
| KR (1) | KR20030030998A (hr) |
| AT (1) | ATE493112T1 (hr) |
| AU (1) | AU2001267504A1 (hr) |
| BG (1) | BG64887B1 (hr) |
| BR (1) | BR0003852A (hr) |
| CA (1) | CA2413188A1 (hr) |
| CZ (1) | CZ296192B6 (hr) |
| DE (2) | DE20009841U1 (hr) |
| EE (1) | EE04769B1 (hr) |
| HR (1) | HRP20000559A2 (hr) |
| HU (1) | HUP0003408A2 (hr) |
| PL (1) | PL198950B1 (hr) |
| RU (1) | RU2237468C2 (hr) |
| SK (1) | SK286019B6 (hr) |
| UA (1) | UA72734C2 (hr) |
| WO (1) | WO2001091719A1 (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE20009841U1 (de) * | 2000-05-31 | 2001-10-25 | Phyt-Immun GmbH, 66424 Homburg | Nasensalbe auf Basis von Vaselin |
| JP4614423B2 (ja) * | 2004-04-30 | 2011-01-19 | フマキラー株式会社 | アレルギー性鼻炎用鼻腔用組成物 |
| JP2006008516A (ja) * | 2004-06-21 | 2006-01-12 | Nippon Kenko Kagaku Kenkyu Center:Kk | 鼻孔花粉症予防用軟膏、及び、鼻孔花粉症予防用ステック状軟膏 |
| JP2006312635A (ja) * | 2005-04-08 | 2006-11-16 | Hinode Sangyo Kk | 鼻腔壁塗布組成物 |
| NL2001342C2 (nl) * | 2008-02-20 | 2009-08-24 | Cornelis Boegem | Balsem voor het afdekken van slijmvliezen tegen in de lucht aanwezige allergene stoffen, het gebruik van de balsem en een applicator voor de balsem. |
| JP5337984B2 (ja) * | 2008-11-07 | 2013-11-06 | アース製薬株式会社 | 鼻腔内塗布製剤及び鼻腔内におけるダレを防止する方法 |
| WO2013049539A1 (en) * | 2011-09-30 | 2013-04-04 | Mcneil-Ppc, Inc. | A method of blocking or trapping allergens |
| CN112076148A (zh) * | 2019-06-12 | 2020-12-15 | 陕西佰傲再生医学有限公司 | 鼻用抗过敏凝胶及制备方法 |
| AU2020230306A1 (en) * | 2020-09-10 | 2022-03-24 | Dao Cheng Song | It is a method to suppress/cure hay fever. Having some moisturiser (Lip Balm, Papaw Ointment) to wax around the inner nose it can effectively suppress hay fever. This invention is a guide for any manufacture interested in creating a product that consists of a similar type of ingredients and creating a specialised medical item, designed a sole purpose for coping hay fever. |
| JP7074388B1 (ja) * | 2022-01-25 | 2022-05-24 | 株式会社オフィスシステムサービス | 鼻用の外用剤 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2095092A (en) * | 1936-02-21 | 1937-10-05 | Clorox Chemical Co | Ointment |
| DE3010572C2 (de) * | 1980-03-19 | 1982-05-06 | Süess, Hans R., Dr., Starrkirch | Hautpflege- und Hautschutzpräparate |
| DE3416209A1 (de) * | 1984-05-02 | 1985-11-21 | Mohamed Roshdy Dr Ismail | Zubereitungen zur behandlung von augen |
| ES2053678T3 (es) * | 1987-11-13 | 1994-08-01 | Asta Medica Ag | Procedimiento para preparar un medicamento con contenido de azelastina para la aplicacion nasal y/u ocular. |
| DE4117887C2 (de) * | 1990-06-09 | 1993-12-16 | Siegfried Rochler | Verwendung von pharmazeutisch/kosmetisch als Vaselin definierten gesättigten Kohlenwasserstoffen als Nasensalbe zur Prophylaxe von inhalationsallergischen Reaktionen |
| HUT63060A (en) * | 1991-08-22 | 1993-07-28 | Hoechst Ag | Process for producing pharmaceutical compositions locally applicable on nose and eye, comprising bradykinin antagonists |
| DE4438589A1 (de) * | 1994-10-28 | 1995-03-23 | Reingard Dr Muenster | Nasentherapeutikum |
| DE19544905A1 (de) * | 1995-12-01 | 1997-06-05 | Robugen Gmbh | Verfahren zur Herstellung von Pflanzenextrakten |
| US5972327A (en) * | 1997-10-22 | 1999-10-26 | Lin; Matthew M. | Method of treating allergic rhinitis by delivering medication via the nasal vestibules |
| JPH11246416A (ja) * | 1998-03-05 | 1999-09-14 | Nof Corp | 点鼻用添加剤及び点鼻薬 |
| DE20002395U1 (de) * | 2000-02-13 | 2000-05-25 | Febena Pharma GmbH, 50825 Köln | Creme, insbesondere zur äußeren Anwendung auf der Nasenhaut |
| DE20009841U1 (de) * | 2000-05-31 | 2001-10-25 | Phyt-Immun GmbH, 66424 Homburg | Nasensalbe auf Basis von Vaselin |
-
2000
- 2000-05-31 DE DE20009841U patent/DE20009841U1/de not_active Expired - Lifetime
- 2000-08-22 CZ CZ20003062A patent/CZ296192B6/cs not_active IP Right Cessation
- 2000-08-24 SK SK1281-2000A patent/SK286019B6/sk not_active IP Right Cessation
- 2000-08-24 EE EEP200000375A patent/EE04769B1/xx not_active IP Right Cessation
- 2000-08-25 RU RU2000122478/15A patent/RU2237468C2/ru not_active IP Right Cessation
- 2000-08-25 HU HU0003408A patent/HUP0003408A2/hu unknown
- 2000-08-25 PL PL342179A patent/PL198950B1/pl not_active IP Right Cessation
- 2000-08-27 UA UA2000085033A patent/UA72734C2/uk unknown
- 2000-08-28 HR HR20000559A patent/HRP20000559A2/hr not_active Application Discontinuation
- 2000-08-28 JP JP2000257825A patent/JP2001342131A/ja active Pending
- 2000-08-28 BR BR0003852-0A patent/BR0003852A/pt not_active IP Right Cessation
- 2000-08-28 BG BG104714A patent/BG64887B1/bg unknown
- 2000-08-29 EP EP00118143A patent/EP1159958A1/de not_active Withdrawn
-
2001
- 2001-05-31 CA CA002413188A patent/CA2413188A1/en not_active Abandoned
- 2001-05-31 EP EP01945223A patent/EP1286657B1/de not_active Expired - Lifetime
- 2001-05-31 AU AU2001267504A patent/AU2001267504A1/en not_active Abandoned
- 2001-05-31 US US10/296,934 patent/US20030161899A1/en not_active Abandoned
- 2001-05-31 DE DE50115757T patent/DE50115757D1/de not_active Expired - Lifetime
- 2001-05-31 AT AT01945223T patent/ATE493112T1/de active
- 2001-05-31 KR KR1020027016096A patent/KR20030030998A/ko active Search and Examination
- 2001-05-31 WO PCT/EP2001/006197 patent/WO2001091719A1/de active Application Filing
-
2002
- 2002-02-14 US US10/077,259 patent/US20020082305A1/en not_active Abandoned
-
2006
- 2006-05-29 JP JP2006148823A patent/JP2006316063A/ja active Pending
-
2012
- 2012-05-14 US US13/470,541 patent/US20120308671A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1286657B1 (de) | 2010-12-29 |
| SK12812000A3 (sk) | 2001-12-03 |
| DE50115757D1 (de) | 2011-02-10 |
| EE200000375A (et) | 2002-02-15 |
| EP1286657A1 (de) | 2003-03-05 |
| RU2237468C2 (ru) | 2004-10-10 |
| ATE493112T1 (de) | 2011-01-15 |
| SK286019B6 (sk) | 2008-01-07 |
| PL198950B1 (pl) | 2008-08-29 |
| HUP0003408A2 (en) | 2002-09-28 |
| KR20030030998A (ko) | 2003-04-18 |
| UA72734C2 (en) | 2005-04-15 |
| JP2006316063A (ja) | 2006-11-24 |
| BG64887B1 (bg) | 2006-08-31 |
| US20030161899A1 (en) | 2003-08-28 |
| JP2001342131A (ja) | 2001-12-11 |
| CZ296192B6 (cs) | 2006-02-15 |
| BG104714A (en) | 2002-05-31 |
| PL342179A1 (en) | 2001-12-03 |
| US20020082305A1 (en) | 2002-06-27 |
| CZ20003062A3 (cs) | 2002-01-16 |
| AU2001267504A1 (en) | 2001-12-11 |
| BR0003852A (pt) | 2002-07-23 |
| WO2001091719A1 (de) | 2001-12-06 |
| DE20009841U1 (de) | 2001-10-25 |
| EP1159958A1 (de) | 2001-12-05 |
| CA2413188A1 (en) | 2001-12-06 |
| EE04769B1 (et) | 2007-02-15 |
| US20120308671A1 (en) | 2012-12-06 |
| HU0003408D0 (en) | 2000-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20120308671A1 (en) | Nasal ointment based on white petroleum jelly | |
| BR9913148A (pt) | Composições mucoadesivas lìquidas orais | |
| CA2726234A1 (en) | Antihistamine and antihistamine-like nasal application, products, and method | |
| EP3331498A1 (en) | A nasal composition | |
| Asero | Effects of birch pollen SIT on apple allergy: a matter of dosage? | |
| US9750706B2 (en) | Electrostatically charged nasal application method and product for micro-filtration | |
| JP2001240547A (ja) | 花粉症抑制剤 | |
| JP2010111638A (ja) | 鼻腔内塗布製剤 | |
| NO20010831L (no) | Orale flytende mukoadhesive sammensetninger | |
| JP2012509250A (ja) | 抗ヒスタミン及び抗ヒスタミン様経鼻適用製品及び方法 | |
| MX2012008419A (es) | Una composicion mejorada a base de un terpemoide y cloretona ademas de su uso en articulos nasales. | |
| JP4614423B2 (ja) | アレルギー性鼻炎用鼻腔用組成物 | |
| DE4117887C2 (de) | Verwendung von pharmazeutisch/kosmetisch als Vaselin definierten gesättigten Kohlenwasserstoffen als Nasensalbe zur Prophylaxe von inhalationsallergischen Reaktionen | |
| JP6586450B2 (ja) | アレルゲン抗体およびそれを有する組成物 | |
| Archer et al. | Amelioration for allergic rhinitis and asthma. The treated yeast milmed and physical exercise | |
| WO2002022120A1 (en) | Pain reliever and method of use | |
| AT501041A4 (de) | Therapeutisches system zur transmukosolen applikation eines vasokonstriktors durch die nasenschleimhaut | |
| US20210069276A1 (en) | Ear spray device and ear protection composition for preventing water related ear canal disorders | |
| RU2068701C1 (ru) | Средство для лечения острых респираторных заболеваний | |
| TR201502140A2 (tr) | Uçuk tedavisinde etkili krem. | |
| KR20000031276A (ko) | 콧 속을 세척하는 세정액의 제조방법 (비염 예방 완화) | |
| DE10120610A1 (de) | Nasenschleimhauttherapeutikum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20090821 Year of fee payment: 10 |
|
| ODBI | Application refused |